<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02164110</url>
  </required_header>
  <id_info>
    <org_study_id>UBC301</org_study_id>
    <nct_id>NCT02164110</nct_id>
  </id_info>
  <brief_title>To Evaluate the Efficacy (Immunogenicity) and Safety of Euvichol in Healthy Adults and Children</brief_title>
  <official_title>A Randomized, Single Blind, Multicenter, Therapeutic Confirmatory Study to Assess the Efficacy (Immunogenicity) and Safety of Euvichol in Healthy Adults and Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>EuBiologics Co.,Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Instituto Universitario IVI</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>EuBiologics Co.,Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy (Immunogenicity) and Safety of Euvichol
      in Healthy Adults and Children.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomized, single blind, multicenter, therapeutic confirmatory study to assess the
      efficacy (immunogenicity) and safety of Euvichol in healthy adults and children
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy</measure>
    <time_frame>14 days after second doses</time_frame>
    <description>Proportion of subjects exhibiting 4-fold or greater rises in titers of anti-V. cholera O1 antibody, relative to baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety</measure>
    <time_frame>From first shot to 14 days after second dose</time_frame>
    <description>Type and frequency of solicited adverse event type (Day 0 ~ 6), Type and frequency of unsolicited adverse event type (Day 0 ~ Day 28)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy</measure>
    <time_frame>14 days after second doses</time_frame>
    <description>1. Proportion of subjects exhibiting 4-fold or greater rises in titers of anti-V. cholera O139 antibody, relative to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>From first shot to 14 days after second dose</time_frame>
    <description>1. Change from baseline in vital signs and physical examination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy</measure>
    <time_frame>14 days after second doses</time_frame>
    <description>1. Geometric Mean Titer (GMT) and Geometric Mean Ratio (GMR) as measured by each anti-V. cholera antibody titer at Week 2 (Visit 3) after the second dose as compared to prior to investigational product dosing (Visit 1).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>14 days after second doses</time_frame>
    <description>1. Change from baseline in laboratory tests (hematologic test, blood chemistry test, urinalysis) to be performed only in subjects who participate in the Pivotal study.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">3632</enrollment>
  <condition>Prevention Harmful Effects</condition>
  <arm_group>
    <arm_group_label>Euvichol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Number of doses and intervals: two doses/Weeks 0 and 2
Method of administration: oral administration
Dose of drug to be administered: 1.5 mL/dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Shanchol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Number of doses and intervals: two doses/Weeks 0 and 2
Method of administration: oral administration
Dose of drug to be administered: 1.5 mL/dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Euvichol</intervention_name>
    <description>Number of doses and intervals: two doses/Weeks 0 and 2
Method of administration: oral administration
Dose of drug to be administered: 1.5 mL/dose</description>
    <arm_group_label>Euvichol</arm_group_label>
    <other_name>Oral Cholerae Vaccine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Shanchol</intervention_name>
    <description>Number of doses and intervals: two doses/Weeks 0 and 2
Method of administration: oral administration
Dose of drug to be administered: 1.5 mL/dose</description>
    <arm_group_label>Shanchol</arm_group_label>
    <other_name>Oral cholera vaccine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Written informed consent to study participation voluntarily provided by an individual
             or his/her legally acceptable representative.

          2. Age of 1 ~ 40 years

          3. An individual who can be followed up during the study period and is capable of
             complying with the study requirements.

        Exclusion Criteria:

          1. History of hypersensitivity reactions to other preventative vaccinations.

          2. Immune function disorders including immunodeficiency diseases.

          3. An individual thought to have difficulty participating in the study due to severe
             chronic diseases, based on the judgment of the investigator.

          4. 38â„ƒ or higher body temperature measured prior to investigational product dosing.

          5. Abdominal pain, nausea, vomiting, or decreased appetite within 24 hours prior to study
             initiation.

          6. Diarrhea or administration of antidiarrheal drugs or antibiotics to treat diarrhea
             within 1 week prior to study initiation.

          7. Other vaccination within 1 week prior to study initiation or planned vaccination
             during the study.

          8. Diarrhea or abdominal pain lasting 2 weeks or longer within 6 months prior to study
             initiation.

          9. Participation in another clinical trial with investigational product dosing within 1
             month prior to study initiation.

         10. Pregnant or lactating women.

         11. An individual thought to have difficulty participating in the study due to other
             reasons, based on the judgment of the investigator

         12. Applicable to the Pivotal study only: history of cholera vaccinations or history of
             cholera.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roberto A. Espos, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>De La Salle University Hospital Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Antonio D. Ligsay, MD</name>
      <address>
        <city>Quezon City</city>
        <zip>4332</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Philippines</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 27, 2014</study_first_submitted>
  <study_first_submitted_qc>June 12, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 16, 2014</study_first_posted>
  <last_update_submitted>December 4, 2014</last_update_submitted>
  <last_update_submitted_qc>December 4, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 8, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

